Dear OncoLink "Ask The Experts,"
My friend has very recently been diagnosed with a grade 4 Glioblastoma. She begins radiation therapy (XRT) next week on a palliative basis. Is there any evidence that the use of the drug Temodar (temozolomide) would improve her survival, and if there is, what would a course of this drug entail?
Robert Lustig MD FACR, Clinical Associate Professor, Department of Radiation Oncology, University of Pennsylvania, responds:
Glioblastoma multiforme is a grade IV (out of IV) astrocytoma, which is a very aggressive primary cancer of the brain. The drug temozolomide, or Temodar, is now part of the standard of care in glioblastoma treatment. It is given daily at a dose of 75 mg/m 2 (based on body size) starting on day one of radiation and continuing until the last day. After a one month rest, temozolomide is then restarted at a higher dose for 5 days, followed by a 3-week rest, and continued in this way until disease progression.
Nov 23, 2012 - Uninsured patients undergoing a craniotomy procedure for a brain tumor have higher in-hospital postoperative mortality rates than insured patients, according to research published in the November issue of the Archives of Surgery.
Jul 31, 2014
Mar 14, 2011